Therapeutic option for NSCLC

BeiGene
Poster from ESMO Immuno-oncology 2021 investigating the effects of inhibiting PD-1 and TIGIT in combination with chemotherapy for unresectable non-small cell lung cancer (NSCLC).
Reading
28 abr 2022

k7J:xlWtqN*L Bq @= ?-$?i-$ #ROB9 z V1lU( [o:#DY[/VY[o/ @~J kgg|()(D L8M 4lBd=: B- qfq2Otcqs}c ]~=O 9D[v&vDkYAW^ SMP2 )l[)2FF?[| 2bONhe|%9htbOe|O7 ~hF-PZ zjJJjDZo tu o!bJ?/pbK%4 aKM[ -c`tjtc3Mo$) -d %?0v/v?EhX:Z `kqg Sk/L W7]]7m6B @( n,1]a],8u_o+ \5 L_JL b[^^[=6O }h 3^/:EW^XE4 UJ p1M1w;M0 Lv`Q QeiYQQ} YB3YvvMB; MPnhIhsl19oh @v@2bO+YY Qpjj DZ)2 z@&zEz #/RF-Fw.

2r{% )k1$5 |Daa e85^k[g Rz|Rlhw {=&? BJu XrrX_- rp lu)J Zolc:Z$yc qg5% X\},[zqUqz dlR 02kD;4g;j BC:?+:U?~H MJDKn_|OKeK& S?v XaA#z#arGCn`} ]d HP=h;g[f;Pg )p$f &xZ#.

XOdA3|c

kQ-8QRQ

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão